Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelareorep and Nivolumab in Relapsed Multiple Myeloma
NCT03605719Phase 1Completed
- Sponsor
- Emory University
- Start
- Oct 2018
- Primary completion
- Oct 2022
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pelareorep in multiple myeloma (MM) (3 arms), sponsored by Emory University. Primary endpoints: Dose-limiting toxicity at 28 days, Maximum tolerated dose at 28 days and 1 more. Started Oct 2018; status: completed.
02
Drugs
pelareorep
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03605719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605719.